RIGEL PHARMACEUTICALS INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $20.4m $4.5m $44.5m $59.3m $108.6m $149.2m $120.2m $116.9m $179.3m $294.3m
Cost of Revenue $2.1m $466k $287k $906k $895k $1.1m $1.7m $7.1m $18.6m $19.6m
Gross Profit (Calculated) (derived) $18.3m $4.0m $44.2m $58.4m $107.7m $148.2m $118.5m $109.8m $160.6m $274.7m
Operating expenses:
Operating Income (Loss) ($69.7m) ($79.6m) ($72.7m) ($69.1m) ($29.0m) ($12.5m) ($55.5m) ($20.5m) $24.2m $125.5m
Additional Financial Items
Amortization of Intangible Assets $100k $1.1m $2.1m $2.4m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $69.7m $79.6m $72.7m $69.1m $29.0m ($17.3m) ($58.6m) ($25.1m) $18.4m $121.8m
Net Income (Loss) Attributable to Parent ($69.2m) ($78.0m) ($70.5m) ($66.9m) ($29.7m) ($17.9m) ($58.6m) ($25.1m) $17.5m $367.0m
Net Income (Loss) Available to Common Stockholders, Basic ($69.2m) ($78.0m) ($70.5m) ($66.9m) ($29.7m) ($17.9m) ($58.6m) ($25.1m) $17.5m $367.0m
Earnings Per Share, Basic ($0.40) ($0.18) ($0.11) ($0.34) ($0.14) $0.99 $20.40
Earnings Per Share, Diluted ($0.11) ($0.34) ($0.14) $0.99 $19.48
Weighted Average Number of Shares Outstanding, Basic 170.5m 172.4m 174.0m 17.6m 18.0m
Weighted Average Number of Shares Outstanding, Diluted 170.5m 172.4m 174.0m 17.7m 18.8m
Research and Development Expense $33.3m
General and Administrative Expense $20.9m $37.8m
Selling, General and Administrative Expense $20.9m $37.8m $70.0m $74.6m $76.6m $91.9m $112.5m $105.7m $113.1m $115.9m
Interest Expense (non-operating) $7.3m
Costs and Expenses $90.1m $84.1m $117.2m $128.4m $137.6m $161.7m $175.8m $137.4m $155.1m $168.8m
Current Income Tax Expense (Benefit) $655k
Interest Expense $335k $1.4m $4.9m $3.7m $6.9m $7.9m $7.3m
Income Tax Expense (Benefit) $0 $0 $0 $605k $881k ($245.2m)